Halozyme is relatively low-beta and an ideal stock in the biotech sector for a covered call trade with good liquidity on ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2024 financial and ...

Leerink Partners analyst David Risinger maintained a Hold rating on Halozyme (HALO – Research Report) yesterday and set a price target of ...

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Halozyme (HALO – Research Report) and keeping the price target at ...

On Friday, Halozyme Therapeutics, Inc. (HALO) stock saw a decline, ending the day at $49.25 which represents a decrease of $-0.05 or -0.10% from the prior close of $49.3. The stock opened at $49.35 ...

On Monday, Halozyme Therapeutics, Inc. (HALO) stock saw a decline, ending the day at $51.77 which represents a decrease of $-0.84 or -1.60% from the prior close of $52.61. The stock opened at $52.6 ...

Market volatility in Q3 was driven by softer-than-expected US employment data, but resilient earnings and rate cuts led to a ...

The Board of Directors of TransAlta Corporation declared a quarterly dividend of $0.06 per common share payable on January 1, ...

The National Institutes of Health (NIH) has launched a proof-of-concept precision medicine clinical trial to test new treatment combinations targeting specific genetic changes in the cancer cells of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...